Sorrento Therapeutics, Inc.
Known title: 10% OwnerCIK: 0000850261
Associated companies
Transaction History
| CELU | ▼ Sell | Open Market | 6,307,158 | — | 10/5/2023 | View on chart |
| CELU | ▼ Sell | Open Market | 9,064,539 | — | 9/29/2023 | View on chart |
| SCLX | ▼ Sell | Open Market | 60,068,585 | — | 9/21/2023 | View on chart |
| SCLX | ▼ Sell | Other | 73,740,795 | $0 | 1/19/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Celularity Q1 2027 EPS Up, Announces Partner & Board Member
Celularity posted a first‑quarter 2027 earnings per share of $0.02, up from a loss of $0.84 a year earlier, while sales fell to $3.85 million from $11.43 million. The company will open the Fontaine Vitale facility with its strategic partner and added Naveen Jain to its board. It also closed a $10 million private placement of senior secured convertible notes and warrants, part of a $28 million recapitalization plan.
Celularity Q1 2027 EPS Up, Announces Partner & Board Member. Celularity posted a first‑quarter 2027 earnings per share of $0.02, up from a loss of $0.84 a year earlier, while sales fell to $3.85 million from $11.43 million. The company will open the Fontaine Vitale facility with its strategic partner and added Naveen Jain to its board. It also closed a $10 million private placement of senior secured convertible notes and warrants, part of a $28 million recapitalization plan.